Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3684 participants.

Also called NCT06096909

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,684 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06096909
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06096909. Randomized; double masking; primary purpose treatment. Start 2023-11-11 (actual); primary completion 2028-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Condition
Acute Coronary Syndrome
Condition
Non ST Segment Elevation Acute Coronary Syndrome
Condition
Lipid Lowering, Vascular Inflammation
Intervention (Drug)
Tafolecimab
Intervention (Drug)
Cholesterol Absorption Inhibitor
Intervention (Drug)
Statin
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)
Collaborator
Innovent Biologics, Inc. (class: other)

Record details

Record id
cardio:ct-nct06096909
Content hash
201ba2b830857f5f1cc451f9c989efefdb5be1489667135249a3c334c884741c